Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials
| العنوان: | Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials |
|---|---|
| المؤلفون: | Xinbin Zhou, Min Zhu, Shenjie Chen, Wei Mao, Yuangang Qiu, Jin Dai, Junyi Hua, Xiaoming Xu |
| المصدر: | Scientific Reports Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017) |
| بيانات النشر: | Nature Publishing Group UK, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | medicine.medical_specialty, medicine.medical_treatment, lcsh:Medicine, Constriction, Pathologic, 030204 cardiovascular system & hematology, Coronary Angiography, Article, law.invention, Coronary Restenosis, Rosiglitazone, 03 medical and health sciences, 0302 clinical medicine, Percutaneous Coronary Intervention, Restenosis, Randomized controlled trial, law, Risk Factors, Angioplasty, Internal medicine, Myocardial Revascularization, Odds Ratio, Medicine, Humans, 030212 general & internal medicine, Angioplasty, Balloon, Coronary, lcsh:Science, Randomized Controlled Trials as Topic, Multidisciplinary, Pioglitazone, business.industry, lcsh:R, Percutaneous coronary intervention, Drug-Eluting Stents, medicine.disease, Treatment Outcome, Conventional PCI, Cardiology, lcsh:Q, Stents, Thiazolidinediones, business, Mace, medicine.drug |
| الوصف: | In-stent restenosis (ISR) remains the leading problem encountered after percutaneous coronary intervention (PCI). Thiazolidinediones (TZDs) has been shown to be associated with reduced ISR and target lesion revascularization (TLR); however, the results are inconsistent, especially between rosiglitazone and pioglitazone. In this study, fourteen RCTs with a total of 1350 patients were finally included through a systematical literature search of Embase, Pubmed, the Cochrane Library, and ClinicalTrials.gov from inception to January 31, 2017. The follow-up duration of the included trials ranged from 6 months to 18 months. The results demonstrated that TZDs treatment is associated with significantly reduced risk of TLR (RR:0.45, 95%CI 0.30 to 0.67 for pioglitazone, RR:0.68, 95%CI 0.46 to 1.00 for rosiglitazone). Pioglitazone is associated with significantly reduced risks of ISR (RR:0.47, 95%CI 0.27 to 0.81), major adverse cardiac events (MACE) (RR:0.44, 95%CI 0.30 to 0.64) and neointimal area (SMD: −0.585, 95%CI −0.910 to −0.261). No significant relationship was observed between rosiglitazone and ISR (RR:0.91, 95%CI 0.39 to 2.12), MACE (RR:0.73, 95%CI 0.53 to 1.00) and neointimal area (SMD: −0.164, 95%CI −1.146 to 0.818). This meta-analysis demonstrated that TZDs treatment is associated with significant reduction in ISR, TLR and MACE for patients after PCI. Pioglitazone treatment seems to have more beneficial effects than rosiglitazone and no significantly increased cardiovascular risk was detected for both agents. |
| اللغة: | English |
| تدمد: | 2045-2322 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d367d03c666a7c4484d972b0ab0e6d7Test http://europepmc.org/articles/PMC5663835Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3d367d03c666a7c4484d972b0ab0e6d7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20452322 |
|---|